These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30548896)

  • 1. Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation.
    Tedesco-Silva H; Del Carmen Rial M; Cruz Santiago J; Mazzali M; Pacheco-Silva A; Torres R
    Clin Transplant; 2019 Feb; 33(2):e13464. PubMed ID: 30548896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG; Stephan AG; Masri MA
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of sirolimus-based immunosuppression, fifteen years post-live-donor kidney transplantation: Single-center experience.
    Hamdy AF; Elhadedy MA; Donia AF; Taha NM; Bakr MA
    Clin Transplant; 2019 Feb; 33(2):e13463. PubMed ID: 30548935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.
    Meiser B; Buchholz S; Kaczmarek I
    Curr Opin Organ Transplant; 2011 Oct; 16(5):522-8. PubMed ID: 21836511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
    Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
    Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
    Höcker B; Tönshoff B
    Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
    Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.